ArticleBMC infectious diseases2025
A case report of severe Mycoplasma pneumoniae pneumonia complicated by plastic bronchitis and Kawasaki disease.
Article in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Kawasaki disease shock syndrome with pulmonary involvement in a child: a case report.Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundWe report the first documented case of macrolide-resistant Mycoplasma pneumoniae (MRMP) infection simultaneously complicated by both plastic bronchitis (PB) and Kawasaki disease (KD), expanding our understanding of severe MRMP-associated immune dysregulation. CASE PRESENTATION: A 7-year-old male presented with persistent high fever (39.8 °C), paroxysmal cough, and mucocutaneous manifestations. Diagnosis was established through multiple modalities: chest CT revealed bilateral consolidation with segmental airway narrowing; bronchoscopy demonstrated characteristic bronchial casts with focal mucosal necrosis; echocardiography showed right coronary artery dilation (Z-score + 2.334); and targeted next-generation sequencing (tNGS) identified MRMP with the A2063G mutation, alongside Streptococcus pneumoniae and Staphylococcus aureus co-infections. Treatment included oral doxycycline after macrolide failure, high-dose IVIG (2 g/kg), methylprednisolone (3 mg/kg/day), and therapeutic bronchoscopy. Complete resolution of coronary dilation and respiratory symptoms was achieved by the one-month follow-up.
conclusionsThis unprecedented case demonstrates how MRMP infection can trigger simultaneous, severe immune-mediated complications through shared inflammatory pathways. In regions with high MRMP prevalence (> 90%), clinicians should maintain vigilance for atypical manifestations in refractory pneumonia. Early bronchoscopy and tNGS for comprehensive pathogen identification are essential, while combined therapy with appropriate alternative antibiotics, corticosteroids, and IVIG can effectively manage these complex cases. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.